Search

We examined pre-mobilization blood CD34+ cell count to predict ability to mobilize adequate peripheral blood progenitor cells (PBPC) in 106 cancer patients and 36 allogeneic donors. Mean pre-mobilization therapy blood CD34+ cell count was 3.1 cells × 106/l (s.d.=3.9, r=0.3–37) and mean CD34+ cells collected were 5.3 × 106 cells/kg/leukapheresis procedure (s.d.=7.0, r=0.03–53). Yields correlated with pre-mobilization CD34+ cells × 106/l (r=0.37, P-value<0.0001); correlation was stronger in allogeneic donors (r=0.56, P-value=0.0004) and males (r=0.46, P-value<0.0001). Based on classification and regression tree multivariate analysis, the predictive value of pre-mobilization blood CD34+ cell count was confounded by other variables, including age, gender, mobilization regimen and malignancy type. We generated an algorithm to predict a minimum PBPC yield of 1 × 106 CD34+ cells/kg/leukapheresis procedure after mobilization. A threshold pre-mobilization blood CD34+ cell count of 2.65 cells × 106/l was the most important decision point in predicting successful mobilization. Only 2% of subjects with pre-mobilization blood CD34+ cell counts >2.65 cells × 106/l did not achieve the minimum per apheresis, whereas 24% with pre-mobilization values below threshold had inadequate mobilization. Prospectively identifying individuals at risk for mobilization failure would allow for improved treatment planning, resource utilization and time saving.Bone Marrow Transplantation (2006) 38, 189–196. doi:10.1038/sj.bmt.1705431 [ABSTRACT FROM AUTHOR]